Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ChemoCentryx

Explore full profile

Develops orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractants

San Carlos, United StatesFounded 1997Biotech & Life Sciences
Valuation $708M Market cap · 2026
Revenue $90M Latest reported FY

About ChemoCentryx

ChemoCentryx was founded in 1997 by Dr. Thomas Schall, a pioneer in chemokine research. The company focused on developing orally-administered therapeutics for the treatment of cancer, autoimmune diseases, and other serious conditions. Dr. Schall's vision was to harness the power of chemokines to create targeted therapies that could address unmet medical needs.

Over the years, ChemoCentryx made significant strides in the biopharmaceutical industry, raising a total of $80.5 million over five funding rounds. The company's innovative approach and dedication to developing treatments for rare diseases caught the attention of major players in the pharmaceutical industry.

A pivotal moment in ChemoCentryx's journey came in August 2022, when Amgen, a leading biotechnology company, acquired ChemoCentryx for $3.7 billion. This acquisition marked a significant milestone for ChemoCentryx, providing the company with the resources and support needed to further its mission of developing life-changing therapies.

Today, ChemoCentryx's legacy continues under the Amgen umbrella, as it remains committed to advancing the field of biopharmaceuticals and improving the lives of patients worldwide.

Source: Dealroom company data

At a glance

Status
Listed
Founded
1997
Headquarters
San Carlos, United States
Listing
IPO 2012
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierColt$25–100M revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Alta Partners
  • HBM Healthcare Investments
  • OrbiMed
  • Gimv
  • HealthCap

Series B and later3 investors entered at this stage

  • Jennison Associates
  • Bio-Techne
  • Hercules Capital

Talent

Book a demo to see the people
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States96%
🇮🇳 India4%
2 countries shown

Patents

Estimated portfolio value
$550M

151 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ChemoCentryx on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ChemoCentryx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles